Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
While low-volatility stocks offer a haven in turbulent markets, their perceived safety can sometimes obscure underlying financial weaknesses. We examine three such stocks where calm trading patterns may not justify their current valuations or growth prospects.
While market darlings come and go, a select group of companies achieves sustained outperformance through a powerful trifecta: rising sales, expanding profitability, and efficient capital use. We examine three such names that have delivered triple-digit returns over the past five years.
Major music publishers have launched a massive copyright infringement lawsuit against AI company Anthropic, alleging its Claude AI was trained on a dataset of over 20,000 pirated songs, in a case that could redefine the rules for AI development.
Chinese autonomous driving leader WeRide has launched its proprietary general-purpose simulation model, Genesis, designed to bridge the gap between real-world data and virtual testing. The platform promises to drastically cut development time and costs for AV systems, from advanced driver-assistance features to fully autonomous robotaxis.
Europe relies on China for the rare earth elements essential in transition technologies, but it's making a late bid to end dependency.
Medtronic secures a key European regulatory nod for its latest pulsed field ablation catheter while deepening its collaboration with Mindray, signaling a strategic push into high-growth areas of cardiac care and ambulatory surgery.
As geopolitical tensions and trade concerns weigh on sentiment, a screen of European equities uncovers potential value opportunities, with some companies trading at discounts of nearly 50% to their estimated intrinsic value.
Amidst a backdrop of market uncertainty, investors are turning their attention to resilient companies with strong fundamentals. We spotlight three lesser-known European firms—from construction tech to cybersecurity and fashion retail—that are demonstrating robust growth and strategic positioning for the year ahead.
A group of protesters in Lynwood, California, surrounded and harassed federal air marshals, incorrectly identifying them as immigration enforcement officers. The incident highlights the volatile climate surrounding immigration debates and the risks of misdirected activism.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
In its Q4 2025 earnings call, CNX Resources outlined a disciplined capital strategy for 2026, emphasizing operational resilience amid severe weather and providing updates on its deep Utica shale program, RNG initiatives, and hedging posture. Management signaled a focus on long-term infrastructure catalysts rather than chasing volatile spot gas prices.
SanDisk's Q2 2026 earnings reveal a 31% sequential revenue surge to $3 billion, driven by AI infrastructure build-out. The company highlights a fundamental industry shift towards long-term agreements as data center demand, now the largest NAND market, reshapes commercial dynamics.
A federal judge has issued a temporary restraining order against a Homeland Security rule that required advance notice for congressional visits to ICE facilities, citing 'irreparable harm' to oversight duties amid heightened national scrutiny.
A former American Airlines crew member has filed a high-stakes lawsuit against Airbus, alleging that exposure to contaminated cabin air during a ground incident left her with debilitating neurological symptoms and unable to work, echoing broader industry concerns.
Mayor Zohran Mamdani confirms the rising human toll from the prolonged freeze, with hypothermia suspected in most cases as the city battles historically low temperatures.
